NeOnc Confirms August 12 Phase 2a NEO100 Data Readout, Reports Q2 Cash of $2M
NTHI sits 15% above its 52-week low of $3.005.
Summary
NeOnc completed topline analysis of its fully enrolled Phase 2a NEO100 study in recurrent high-grade glioma and will present results on August 12 — a binary catalyst for this $90M market cap biotech. Q2 financials show just $2M in cash against a $23M H1 loss, though an undrawn $10M related-party credit line and active ATM/shelf provide near-term liquidity. The company also highlighted UAE IND approvals for NEO100 and NEO212 and FDA feedback on NEO212 manufacturing. The August 12 readout is the key event; with a going concern warning and heavy dilution risk already priced in, the data will determine whether the clinical thesis holds.
Updates
· SEC 8-K — Net loss was $14.2 million, or $(0.58) per diluted share, for Q2 2026, with R&D expenses of $2.6 million and G&A of $0.9 million. The company will host a conference call on August 12 at 8:30 a.m. ET.
At the time of this announcement, NTHI was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.8M. The 52-week trading range was $3.01 to $12.99. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.